By Diana Manos December 16, 2019, 2:25 p.m. EST
CVS Health is launching a new precision
medicine strategy for payers that will incorporate genomics and technology.
The new Transform Oncology Care, a
comprehensive oncology management program, will use genomic testing results at
the point-of-prescribing to help patients get started sooner on the best
treatment and also helps match eligible patients to clinical trials, CVS Health
executives say.
CVS has tapped Tempus, a precision medicine
technology company that uses artificial intelligence, to help with the program.
"Timing in cancer care is everything, and
when a patient does not get started on the right treatment, it can result in
progression and higher costs," says Alan Lotvin, MD, executive vice
president and chief transformation officer for CVS Health. "We are the
first company working to make the latest in precision medicine accessible to
more patients and further empower informed treatment decision-making based on a
patient's genetic profile to give them the best chance for successful treatment
and improved quality of life."
Therapeutic regimens that align to National
Comprehensive Cancer Network guidelines, including those matched with the
results of the broad-panel gene sequencing tests, will automatically receive
prior authorization approval, speeding therapy for patients, CVS said.
Ryan Fukushima, chief operating officer of
Tempus, says the collaboration has real potential to personalize treatment for
patients while also reducing the total cost of care.
According to CVS Health, patients diagnosed
with late-stage cancers can benefit from advanced genomic testing; however,
very few eligible patients now receive this type of testing. The new program
will offer these patients a web-based provider portal built into the
e-prescribing workflow to inform oncologists of the availability of Tempus'
broad-panel gene sequencing tests at diagnosis. These tests are more
comprehensive than the single-gene tests that are used today.
The program will also combine nurse-led care
management through CVS Health with a payer's existing programs, CVS says. In
addition, the program enables payers to use value-based care contracts.
Transform Oncology Care also uses the CVS Health's data and integrated systems
to identify patients who could benefit from preventive or screening services.
Transform Oncology Care is available to other
health plans, and Aetna has adopted the program for fully insured commercial
populations and is rolling it out with participating Aetna provider networks in
12 states, CVS says.
CVS Health serves an estimated 38 million
people through traditional, voluntary and consumer-directed health insurance
products.
No comments:
Post a Comment